US10385044B2ActiveUtilityA1
Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists
Est. expiryDec 17, 2034(~8.4 yrs left)· nominal 20-yr term from priority
Inventors:Alan David BorthwickMark MillsJane Theresa BrownJonathan Patrick Thomas CorcoranMaria Beatriz De Castro Vasconcelos GoncalvesSarkis Barret Kalindjian
A61P 25/16A61P 25/14A61P 25/02A61K 31/41A61P 43/00A61P 25/28A61P 25/00A61P 15/10A61K 31/4245C07D 417/04C07D 413/04
88
PatentIndex Score
6
Cited by
61
References
38
Claims
Abstract
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as “BHBA compounds”), which, inter alia, are (selective) retinoic acid receptor beta (RARβ) (e.g., RARβ2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RARβ (e.g., RARPβ2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RARβ (e.g., RARβ2), that are ameliorated by the activation of RARβ (e.g., RARβ2), etc., including, e.g., neurological injuries such as spinal cord injuries.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A method of treatment of a nerve injury, comprising administering to a subject having nerve injury a therapeutically-effective amount of a compound selected from compounds of the following formula, and pharmaceutically acceptable salts thereof:
wherein:
one of X 1 , X 2 , and X 3 is independently O or S;
each of the other two of X 1 , X 2 , and X 3 is N;
Y 1 is independently O or S;
Y 2 is independently CH, CR Y or N;
—R Y is saturated linear or branched C 1-3 alkyl;
—R Q1 is independently —R Q1A , —R Q1B , or —R Q1C ;
—R Q1A is saturated linear or branched C 1-3 alkyl;
—R Q1B is —F, —Cl, —Br, or —I;
—R Q1C is —CF 3 ;
—R Q2 is independently —R Q2A , —R Q2B , or —R Q2C ;
—R Q2A is saturated linear or branched C 1-3 alkyl;
—R Q2B is independently —F, —Cl, —Br, or —I;
—R Q2C is —CF 3 ;
—R Q3 is independently —H or —R Q3X ;
—R Q3X is independently —R Q3A , —R Q3B , —R Q3C , or —R Q3D ;
—R Q3A is saturated linear or branched C 1-3 alkyl;
—R Q3B is saturated linear or branched C 1-3 alkoxy;
—R Q3C is independently —F, —Cl, —Br, or —I;
—R Q3D is —CF 3 ;
—R Q4 is independently —H or —R Q4X ;
—R Q4X is independently —R Q4A , —R Q4B , —R Q4C , or —R Q4D ;
—R Q4A is saturated linear or branched C 1-3 alkyl;
—R Q4B is saturated linear or branched C 1-3 alkoxy;
—R Q4C is independently —F, —Cl, —Br, or —I;
—R Q4D is —CF 3 ;
one of —R P1 and —R P2 is —H or —R P ;
the other of —R P1 and —R P2 is —H;
—R P is independently —R PA , —R PB , —R PC , or —R PD ;
—R PA is saturated linear or branched C 1-3 alkyl;
—R PB is independently —F, —Cl, —Br, or —I;
—R PC is —CF 3 ;
—R PD is independently —NH 2 or —NHR PDD ;
—R PDD is saturated linear or branched C 1-3 alkyl;
—R A is independently —H or —R AA ; and
—R AA is independently saturated linear or branched C 1-4 alkyl, phenyl, or benzyl.
2. A method according to claim 1 , wherein —R A is —H.
3. A method according to claim 2 , wherein:
X 1 is O, X 2 is N, and X 3 is N; or
X 1 is S, X 2 is N, and X 3 is N; or
X 1 is N, X 2 is S, and X 3 is N.
4. A method according to claim 2 , wherein:
X 1 is O; X 2 is N; and X 3 is N.
5. A method according to claim 3 , wherein:
Y 1 is O and Y 2 is CH; or
Y 1 is O and Y 2 is CR Y ; or
Y 1 is O and Y 2 is N; and
—R Y is -Me.
6. A method according to claim 4 , wherein:
Y 1 is O and Y 2 is CH; or
Y 1 is O and Y 2 is CR Y ; or
Y 1 is O and Y 2 is N; and
—R Y is -Me.
7. A method according to claim 3 , wherein:
Y 1 is O; and Y 2 is CH.
8. A method according to claim 4 , wherein:
Y 1 is O; and Y 2 is CH.
9. A method according to claim 5 , wherein:
—R Q1 is independently —R Q1A or —R Q1B ;
—R Q1A is -Me;
—R Q1B is —F or —Cl;
—R Q2 is independently —R Q2A or —R Q2B ;
—R Q2A is -Me;
—R Q2B is —F or —Cl;
—R Q3 is —H; and
—R Q4 is —H.
10. A method according to claim 6 , wherein:
—R Q1 is independently —R Q1A or —R Q1B ;
—R Q1A is -Me;
—R Q1B is —F or —Cl;
—R Q2 is independently —R Q2A or —R Q2B ;
—R Q2A is -Me;
—R Q2B is —F or —Cl;
—R Q3 is —H; and
—R Q4 is —H.
11. A method according to claim 7 , wherein:
—R Q1 is independently —R Q1A or —R Q1B ;
—R Q1A is -Me;
—R Q1B is —F or —Cl;
—R Q2 is independently —R Q2A or —R Q2B ;
—R Q2A is -Me;
—R Q2B is —F or —Cl;
—R Q3 is —H; and
—R Q4 is —H.
12. A method according to claim 8 , wherein:
—R Q1 is independently —R Q1A or —R Q1B ;
—R Q1A is -Me;
—R Q1B is —F or —Cl;
—R Q2 is independently —R Q2A or —R Q2B ;
—R Q2A is -Me;
—R Q2B is —F or —Cl;
—R Q3 is —H; and
—R Q4 is —H.
13. A method according to claim 5 , wherein:
—R Q1 is —R Q1A ;
—R Q1A is -Me;
—R Q2 is —R Q2A ;
—R Q2A is -Me;
—R Q3 is —H; and
—R Q4 is —H.
14. A method according to claim 6 , wherein:
—R Q1 is —R Q1A ;
—R Q1A is -Me;
—R Q2 is —R Q2A ;
—R Q2A is -Me;
—R Q3 is —H; and
—R Q4 is —H.
15. A method according to claim 7 , wherein:
—R Q1 is —R Q1A ;
—R Q1A is -Me;
—R Q2 is —R Q2A ;
—R Q2A is -Me;
—R Q3 is —H; and
—R Q4 is —H.
16. A method according to claim 8 , wherein:
—R Q1 is —R Q1A ;
—R Q1A is -Me;
—R Q2 is —R Q2A ;
—R Q2A is -Me;
—R Q3 is —H; and
—R Q4 is —H.
17. A method according to claim 9 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
18. A method according to claim 10 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
19. A method according to claim 11 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
20. A method according to claim 12 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
21. A method according to claim 13 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
22. A method according to claim 14 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
23. A method according to claim 15 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
24. A method according to claim 16 , wherein:
—R P is independently —R PA or —R PB ;
—R PA is -Me; and
—R PB is independently —F or —Cl.
25. A method according to claim 1 , wherein the compound is a compound of one of the following formulae, or a pharmaceutically acceptable salt thereof:
26. A method according to claim 1 , wherein the nerve injury is a peripheral nervous system (PNS) nerve injury.
27. A method according to claim 1 , wherein the nerve injury is a central nervous system (CNS) nerve injury.
28. A method according to claim 1 , wherein the nerve injury is a spinal cord injury.
29. A method according to claim 1 , wherein the nerve injury is a spinal cord injury caused by trauma.
30. A method according to claim 1 , wherein the nerve injury is an optic nerve injury.
31. A method according to claim 1 , wherein the nerve injury is an optic nerve injury caused by glaucoma.
32. A method of treatment of a nerve injury, comprising administering to a subject having nerve injury a therapeutically-effective amount of a compound of the following formula, or a pharmaceutically acceptable salt thereof:
33. A method according to claim 32 , wherein the nerve injury is a peripheral nervous system (PNS) nerve injury.
34. A method according to claim 32 , wherein the nerve injury is a central nervous system (CNS) nerve injury.
35. A method according to claim 32 , wherein the nerve injury is a spinal cord injury.
36. A method according to claim 32 , wherein the nerve injury is a spinal cord injury caused by trauma.
37. A method according to claim 32 , wherein the nerve injury is an optic nerve injury.
38. A method according to claim 32 , wherein the nerve injury is an optic nerve injury caused by glaucoma.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.